Governor Glenn Youngkin spoke with 8News about AstraZeneca’s recent announcement to build their world’s-largest manufacturing ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.

"gMG race hots up as AstraZeneca’s star candidate meets Phase III targets" was originally created and published by Clinical ...

Intervention/Treatment: The study is testing several interventions, including durvalumab, a known immunotherapy drug, in combination with other novel agents like danvatirsen, oleclumab, MEDI5752, and ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...

Technology has largely been responsible for the US market’s strong gains over the past few months. If investors were scared off big technology for good reason, they have been drawn back to it for ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL trial and promised to share more at an upcoming scientific meeting.

The pharmaceutical giant sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it currently sells for  myasthenia gravis.

Dozens of alumni of a group the State Department has linked to espionage have secured jobs in sensitive industries.

AstraZeneca (AZN) stock is in focus as the company's experimental drug gefurulimab for generalized myasthenia gravis hits ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...